Safety of risdiplam in spinal muscular atrophy patients after short‐term treatment with nusinersen

Abstract Introduction/Aims Following the approval of risdiplam, there are more possibilities for disease‐modifying therapy (DMT) in children with spinal muscular atrophy (SMA). Non‐treatment‐naïve subjects with SMA involved in the JEWELFISH study, designed to evaluate the safety and tolerability of risdiplam, were required to undergo a washout period before receiving risdiplam. This study aims to investigate the safety of administering risdiplam in patients within 90 days of receiving treatment with nusinersen. Methods Data were collected on SMA patients who had undergone treatment with nusinersen, and who then received risdiplam within 90 days of their last dose of nusinersen, including demographic characteristics, information on treatment with nusinersen and risdiplam, adverse events, and laboratory assessments in a follow‐up period of 90 days, presented as median (range). Results A total of 15 children with SMA were reported, including 8 males and 7 females. The median number of doses of previous nusinersen treatment received was 8 (6–17) doses, and the median age at first risdiplam treatment was 4.3 (1.9–11.2) years. Specifically, 8 children received risdiplam 30 days or less after their most recent nusinersen treatment, 2 at 31–60 days after nusinersen, and 5 at 61–89 days post‐nusinersen. Adverse events of pyrexia, pneumonia, vomiting and rash were reported in 4 patients. Discussion Our study showed good safety data on patients who received risdiplam following nusinersen within the washout period of 90 days. This supplements the JEWELFISH study in the era of DMT, providing additional guidance for clinicians, but additional data from other centers is needed.